KAI Pharmaceuticals reports positive results for KAI-1678 in pain reduction

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced preclinical results demonstrating the effectiveness of KAI-1678 in reversing pain (hyperalgesia and allodynia) in multiple preclinical models.

KAI-1678 also was shown to reverse pain more effectively than gabapentin, an industry-standard comparison in pain research. The preclinical results were presented in two posters at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience , taking place in Washington, DC from November 15 - 19. KAI-1678, a first-in-class, isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway (epsilon PKC), is expected to enter Phase 2a clinical testing by the end of 2008.

Stephen D. Harrison, Ph.D., Senior Vice President, Research commented, “The findings being presented at this year's Society for Neuroscience meeting provide additional validation for our program advancing the first isozyme-selective, epsilon PKC inhibitor in the clinic. The localization of epsilon PKC in pain receptor neurons made this a particularly interesting therapeutic target for the modulation of acute pain. Applying our expertise in PKC and in the delivery of peptides into the cell, we were able to create a promising clinical candidate against this target, which will soon progress into mid-stage trials in patients.”

An estimated 50 million people in the United States suffer from some form of persistent pain, while another 25 million suffer acute pain each year as a result of injury or surgery. According to a survey by the American Pain Society, four out of ten people suffering moderate to severe pain were unable to find adequate pain relief.

About KAI-1678

KAI-1678 is an isozyme-selective, small peptide inhibitor of the epsilon protein kinase C pathway. Epsilon PKC is a well-validated target for both inflammatory and neuropathic pain in the preclinical, peer-reviewed literature. KAI's approach is the first to enable the specificity of action required to make epsilon PKC inhibition a viable clinical approach.

KAI-1678 has been shown to be highly effective at reducing pain responses in preclinical models of both neuropathic and inflammatory pain.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Study identifies common skin bacterium as previously unknown culprit behind itch